DERIVATIVES OF PYRIDO [3,2-D] PYRIMIDINE, METHODS FOR PREPARATION THEREOF AND THERAPEUTIC USES THEREOF

• US 20130109693A1
• Filed: 04/28/2011
• Published: 05/02/2013
• Est. Priority Date: 04/28/2010
• Status: Abandoned Application

• Current Assignee: Centre National De La Recherche Scientifique, Universite D'Orleans
• Original Assignee: Centre National De La Recherche Scientifique, Universite D'Orleans
• Inventors: Routier, Sylvain, Dehbi, Oussama, Guillaumet, Grald, Tikad, Abdellatif
• Application Number:
  US13/695,001
• Publication Number:
  US 20130109693A1
• Time in Patent Office: Days
• US Class Current: 514/245
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07D 471/04 Ortho-condensed systems

Abstract

The present invention relates to a compound of the following general formula (I):

• • wherein:
    • R₁ is notably H, a halogen or an aryl group,
    • R₂ is notably a halogen or an aryl group,
    • R₃ is notably a halogen, or an aryl or heteroaryl group, as well as to its pharmaceutically acceptable salts, its hydrates or its polymorphic crystalline structures, its racemates, diastereoisomers or enantiomers,
      except the compound 1-(2,4-diaminopyrido[3,2-d]pyrimidin-7-yl)-3,6,6-trimethyl-6,7-dihydro-1H-indol-4(5H)-one.

Claims

1. A compound of the following general formula (I):

2. The compound of formula (I) according to claim 1, wherein R₁ is selected from the group consisting of:

hydrogen,

halogens,

(hetero)aryls comprising from 5 to 30 carbon atoms.

3. The compound of formula (I) according to claim 1, wherein R₁ represents a phenyl group.

4. The compound of formula (I) according to claim 1, wherein R₂ represents a phenyl group.

5. The compound of formula (I) according to claim 1, wherein R₂ represents a phenyl group substituted with a group OR_α

, R_α

representing H or an alkyl group comprising from 1 to 10 carbon atoms.

13. The compound of formula (I) according to claim 1, wherein R₁ represents H.

14. The compound of formula (I) according to claim 1, wherein R₁ represents H, R₂ represents a phenyl group and R₃ represents a halogen or a phenyl group.

15. The compound of formula (I) according to claim 1, wherein R₁ represents H, R₂ represents a phenyl group substituted with a group OR_α

, R_α

representing H or an alkyl group, comprising from 1 to 10 carbon atoms, and R₃ represents a halogen or a phenyl group substituted with a group OR_α

, R_α

representing H or an alkyl group comprising from 1 to 10 carbon atoms.

16. The compound according to claim 1, of the following formula (I-3):

17. The compound according to claim 1, of the above formula (I-3), wherein R₃ is selected from the group consisting of the following groups:

halogen,

furanyl,

thiophenyl,

pyridyl,

phenyl,

benzothiazolyl, and

a group —

NHR″

_b, R″

_b being selected from the group consisting of the following groups;

phenyl,

pyridyl,

pyrimidinyl,

thiazolyl, and

isoxazolyl.

18. The compound of formula (I) according to claim 1, wherein R₁ represents NHBn.

19. The compound of formula (I) according to claim 1, wherein R₂ represents a —

NH—

(CH₂)₂—

OH group.

20. The compound according to claim 1, of the following formula (I-4):

21. A method for treating or preventing diseases related to a deregulation of CDK1, CDK5, GSK3 and/or DYRK1A kinases comprising a step of administering a pharmaceutically acceptable amount of a compound of formula (I) according to claim 1 to a patient in need thereof.

22. The method according to claim 21, wherein the disease is selected from the group consisting of cancers, Alzheimer'"'"'s disease, Parkinson'"'"'s disease, brain traumas, cerebravascular strokes, renal polycystoses, amyotrophic lateral scleroses, viral infections, auto-immune diseases, neurodegenerative disorders, psoriasis, asthma, atopical dermatitises, trisomia 21 and glomerulonephrites.

6-12. -12. (canceled)